key: cord-0997372-f2lja8p6
authors: El Vally, Abdallahi; Bollahi, Mohamed Abdallahi; Ould Ahmedou Salem, Mohamed Salem; Deida, Jemila; Parola, Philippe; Basco, Leonardo; El Bara, Ahmed; Ouldadallahi, Mohamed; Mohamed Salem Boukhary, Ali Ould
title: Retrospective overview of the coronavirus disease 2019 (COVID-19) outbreak in Mauritania
date: 2020-10-15
journal: New Microbes New Infect
DOI: 10.1016/j.nmni.2020.100788
sha: 738f126b106f31a31a6d8c799846e7bc06cce2a9
doc_id: 997372
cord_uid: f2lja8p6

A COVID-19 outbreak is currently ongoing in Mauritania. Until July 1, 2020, Mauritania health authorities reported 41,862 serological and RT-qPCR tests performed, of which 4,472 (10.7%) were positive for SARS-Cov-2. Males were significantly more affected (57.1%) than females (42.9%). Individuals of the age groups 15–34 (35.8%) and 35–54 (36.6%) years were the most affected. There were 129 (2.9%) deaths, 1,677 (37.5%) recoveries and 2,666 (59.6%) active cases of whom 2,261 (84.8%) were asymptomatic, 394 (14.7%) with mild symptoms and 11 (0.4%) severe cases. A large proportion of fatalities (72%; 85/118) occurred among adults aged ≥ 55 years. Of 4,472 positive cases, 4,241 (94.8%) were infected through contact with a confirmed COVID-19 case, 133 (3.0%) had no contact with confirmed COVID-19 case, and 98 (2.2%) were imported. As a riposte against COVID-19, the Mauritanian authorities announced a set of preventive measures, including closure of land and air borders, nocturne curfew, closure of markets, schools, and universities, and restriction of movement between cities. Control measures include the systematic testing of symptomatic patients, isolation and management of active cases, contact tracing, and quarantine of people who have been in contact with a COVID-19-positive individual. We discuss the efforts of the Mauritanian government to combat this potentially life-threatening pneumonia.

In December 30, 2019, an uncommon pneumonia outbreak of unknown etiology was reported in Wuhan (province of Hubei), China [1] . Viral isolation and molecular analyses indicated a novel coronavirus (family Coronaviridae) provisionally named 2019-nCov [2] .

The International Committee on Taxonomy of Viruses (2020) later designated the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the World Health Organization (WHO) officially named the associated disease '2019-Coronavirus Disease' [3, 4] .

Due to its high infectiveness and person-to-person mode of transmission [5] , the SARS-CoV-2 rapidly spread across China to other countries worldwide, and the WHO emergency committee declared on January 30, 2020, the coronavirus outbreak a global health emergency and a pandemic on March 11, 2020 [4] . As J o u r n a l P r e -p r o o f On April 18, 2020, Mauritania officially announced that the country is coronavirusfree, after the last active case had recovered. However, following a 40-day 'COVID-19-free' period, during which only two cases were registered, the disease resurged on May 12, 2020, and since that time, COVID-19 cases have been registered daily.

In the present study, we address the current situation of COVID-19 in Mauritania, as of July 1, 2020, and discuss the efforts of Mauritanian authorities to combat this potentially life-threatening respiratory illness.

There were three pathways through which the Mauritanian Ministry of Health recruited Covid-19-positive cases: (i) the mobile alert management teams (ii) sentinel reception sites created n collaboration with the army, and (iii) patients attending health facilities with suspected COVID-19 signs and symptoms. 

Using the national case-based surveillance, the present study describes the epidemiological feature of COVID-19 outbreak in Mauritania. A low rate of mortality (2.9%) due to COVID-19 was observed during the period between March 13 and July 1, 2020 in Mauritania. This result is within the range of 1.6-6.5% reported for the same period in some neighboring countries of Mauritania, such as Senegal (1.6%), Morocco (1.8%), Mali (5.3%), and Algeria (6.5%) [9] . Consistent with reports on morbidity and deaths in individuals with COVID-19, the majority of positive patients were males (56.6%) and most deceased patients (72%) were aged ≥ 55 years [11, 12] .

Mauritania has a young population with a majority of its inhabitants belonging to the age group between 24 and 45 years old [13] , which corresponds to the most affected individuals during the current epidemic. However, young people have been reported to be less susceptible to COVID-19 infection than older people aged ≥ 55 years [14] . This is consistent with the high rate of asymptomatic individuals (84.6%) observed among young persons in this study and could be a favorable condition in limiting the mortality rate of the disease. This assumption is supported by a recent study showing that only a small proportion (within the range of 0-10%) of asymptomatic carriers eventually develop symptoms of COVID-19 [15] .

Although the first case of COVID-19 was reported on March 13, 2020, the exponential growth phase in the number of positive cases was observed only from June. This could be due to the fact that the majority of initial cases of COVID-19 were detected among foreigners who had little contact with Mauritanians and the rapid riposte of the health authorities to trace few positive individuals who were in contact with them. The opposite situation was observed after the 40-day 'COVID-19-free' period, during which death of Mauritanians, who apparently had no history of contact with a COVID-19-infected patient, was announced. Increasing growth observed during June could be due to the exponential number of persons tested for COVID-19 during contact tracing.

During the study period, a relatively low prevalence (10.8%) of COVID-19 was detected in Mauritania. Although the age distribution of infected patients was similar to that of the general population in Mauritania, the reported prevalence could be biased because the study population mostly consisted of individuals identified during contact tracing, which may not necessarily represent the general population. To overcome the possible weakness in the reported prevalence, a population based-data on COVID-19 using immunodiagnostic tests that are rapid, less expensive, and easier-to-use than PCR assay in the field are urgently needed.

Moreover, because COVID-19-infected individuals can have mild illness or may be J o u r n a l P r e -p r o o f asymptomatic (and therefore might not be tested for diagnosis or receive medical care), COVID-19 sero-prevalence surveys based on the detection of specific antibodies against SARS-CoV-2 could be more informative about the proportion of persons who have been infected with SARS-CoV-2. These surveys are also suitable and useful for disease surveillance [16] .

To combat COVID-19 epidemic, preventive control measures were rapidly implemented in Mauritania. As a riposte against COVID-19, the Mauritanian authorities through an inter-ministerial committee announced a set of preventive measures, including closure of land and air borders, night curfew, closure of markets, restaurants, cafeterias, schools and universities, prohibition of prayer in mosques, and restriction of population movement between cities. Control measures included the systematic testing of symptomatic patients, isolation and management of active cases, and contact tracing and quarantine of persons who had been in contact with a confirmed COVID-19 individual to prevent onward transmission. A call center received and processed thousands of calls daily.

Also, despite a mediatic controversies, chloroquine or hydroxychloroquine, with or without azithromycin, has been approved as a first line treatment of confirmed COVID-19 cases in many African countries, and was included in the regimen against COVID-19 in Mauritania [17, 18] .

However, as for most national health system in developing countries, Mauritanian national health system was clearly not prepared to manage a sanitary crisis of such magnitude.

For instance, a very limited number of beds in intensive care units existed in health facilities

WHO. Report of the WHO-China Joint Mission on Coronavirus Disease

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center

Clinical management of COVID-19

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

COVID-19 death rates by age and sex and the resulting mortality vulnerability of countries and regions in the world

Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis

Prevalence of asymptomatic SARS-CoV-2 infection: A narrative review

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Chloroquine and COVID-19: a western medical and